(AIM: SAR)

13 November 2013

Sareum Holdings plc

(“Sareum” or “the Company”)

Notice of AGM

The Company announces that a notice has been sent to its shareholders to convene its Annual General Meeting (“AGM”) which is to be held at 10.00 a.m. on 11 December 2013 at the offices of Hybridan LLP, Warnford Court, 29 Throgmorton Street, London EC2N 2AT.

In addition, and further to the announcement of the Company’s final results for the year ended 30 June 2013 released on 10 October 2013, the Company announces that the report and accounts have been posted to those shareholders that requested hard copies.

Both the report and accounts and the notice of AGM will be available on the Company’s website www.sareum.co.uk shortly.

Further information:

Sareum Holdings plc

 

Tim Mitchell, Chief Executive Officer

01223 497 700

Sanlam Securities UK Limited (NOMAD)

Simon Clements

020 7628 2200

Hybridan LLP (Broker)

 

Claire Noyce / William Lynne

020 7947 4350 / 4361

The Communications Portfolio (Media enquiries)

 

Ariane Comstive

ariane.comstive@communications-portfolio.co.uk

020 7536 2028

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licencing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

CHK1 Kinase Inhibitors - CHK1 is important in controlling the way many cancer cells respond to DNA damage, which may be a consequence of the cancer itself, or intentionally caused by chemotherapy or radiotherapy. Inhibition of CHK1 affects the ability of the cell to repair this damage and can therefore potentiate the effect of certain chemotherapeutic drugs.  The candidate CHK1 inhibitor to be developed could potentially treat a range of cancers including pancreatic, bowel and non-small cell lung cancer (NSCLC) in combination with DNA-damaging chemotherapy drugs and/or radiotherapy. The inhibitor could also potentially treat certain neuroblastoma and acute myeloid leukaemia (AML) types when dosed alone.  In September 2013 Sareum entered into a co-development agreement with the Cancer Research Technology Pioneer Fund (CPF) and London Stock Exchange-listed investment company, BACIT Ltd.

Aurora+FLT3 Kinase Inhibitors - Aurora kinase is involved in the control of mitosis (cell division), and FLT3 kinase over-activation is the most common mutation in acute myeloid leukaemia (AML, the most common form of adult leukaemia) patients. Aurora+FLT3 kinase inhibitors also have the potential to treat various other forms of cancer.

TYK2 Kinase Inhibitors – The Tyrosine Kinase 2 (TYK2) small molecule drug discovery programme is focussed on autoimmune and inflammatory disorders such as multiple sclerosis, psoriasis and inflammatory bowel disease. In April 2013, Sareum entered into a co-development agreement with independent nonprofit research and development institute, and autoimmune disease specialists, SRI International.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.  For further information, please visit www.sareum.co.uk